Search Results

Neglected Diseases Caused By Bacterial Infections

Authors: Bechtle, M.; Chen, S.; Efferth, T.

Source: Current Medicinal Chemistry, Volume 17, Number 1, January 2010 , pp. 42-60(19)

Publisher: Bentham Science Publishers

Effects of Prulifloxacin on Cardiac Repolarization in Healthy Subjects: A Randomized, Crossover, Double-Blind versus Placebo, Moxifloxacin-Controlled Study

Authors: >Maria Teresa Rosignoli,; >Giorgio Di Loreto,; Dionisio, Paolo

Source: Clinical Drug Investigation, Volume 30, Number 1, 1 January 2010 , pp. 5-14(10)

Publisher: Adis International

Thorough QT Studies: Questions and Quandaries

Authors: Malik, Marek; Garnett, Christine E.; Zhang, Joanne

Source: Drug Safety, Volume 33, Number 1, 1 January 2010 , pp. 1-14(14)

Publisher: Adis International

Adding moxifloxacin is associated with a shorter time to culture conversion in pulmonary tuberculosis

Authors: Wang, J-Y.; Wang, J-T.; Tsai, T-H.; Hsu, C-L.; Yu, C-J.; Hsueh, P-R.; Lee, L-N.; Yang, P-C.

Source: The International Journal of Tuberculosis and Lung Disease, Volume 14, Number 1, January 2010 , pp. 65-71(7)

Publisher: International Union Against Tuberculosis and Lung Disease

Besifloxacin Ophthalmic Suspension 0.6%

Authors: Carter, Natalie J.; Scott, Lesley J.

Source: Drugs, Volume 70, Number 1, 1 January 2010 , pp. 83-97(15)

Publisher: Adis International

Cutaneous miliary resistant tuberculosis in a patient infected with human immunodeficiency virus: case report and literature review

Authors: Regnier, S.; Ouagari, Z.; Perez, Z. L.; Veziris, N.; Bricaire, F.; Caumes, E.

Source: Clinical & Experimental Dermatology, Volume 34, Number 8, December 2009 , pp. e690-e692(1)

Publisher: Blackwell Publishing

Comparative Analysis of Length of Stay, Total Costs, and Treatment Success between Intravenous Moxifloxacin 400 mg and Levofloxacin 750 mg among Hospitalized Patients with Community-Acquired Pneumonia

Authors: Friedman, Howard; Song, Xue; Crespi, Simone; Navaratnam, Prakash

Source: Value in Health, Volume 12, Number 8, November/December 2009 , pp. 1135-1143(9)

Publisher: Blackwell Publishing

Future treatment options for Gram-positive infections—looking ahead

Authors: Barton, E.; MacGowan, A.

Source: Clinical Microbiology & Infection, Volume 15, Supplement 6, December 2009 , pp. 17-25(9)

Publisher: Blackwell Publishing

Antibiotic therapy in elderly patients with acute exacerbation of chronic bronchitis

Authors: Albertson, Timothy E; Chan, Andrew L

Source: Expert Review of Respiratory Medicine, Volume 3, Number 5, October 2009 , pp. 539-548(10)

Publisher: Expert Reviews

Comparative in vitro activities of nemonoxacin, doripenem, tigecycline and 16 other antimicrobials against Nocardia brasiliensis, Nocardia asteroides and unusual Nocardia species

Authors: Lai, Chih-Cheng; Tan, Che-Kim; Lin, Sheng Hsiang; Liao, Chun-Hsing; Chou, Chien-Hong; Hsu, Hsiao-Leng; Huang, Yu-Tsung; Hsueh, Po-Ren

Source: Journal of Antimicrobial Chemotherapy, Volume 64, Number 1, 14 July 2009 , pp. 73-78(6)

Publisher: Oxford University Press

Levofloxacin trumps moxifloxacin for CAP

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 589, 2009-10-17 , pp. 8-8(1)

Publisher: Adis International

Antituberculars/moxifloxacin: Atopic dermatitis (first report with moxifloxacin) in an elderly patient: case report

Source: Reactions, Volume 1, Number 1274, 2009-10-17 , pp. 10-10(1)

Publisher: Adis International

Pharmacodynamics of moxifloxacin against a high inoculum of Escherichia coli in an in vitro infection model

Authors: Singh, Renu; Ledesma, Kimberly R.; Chang, Kai-Tai; Hou, Jing-Guo; Prince, Randall A.; Tam, Vincent H.

Source: Journal of Antimicrobial Chemotherapy, Volume 64, Number 3, 7 September 2009 , pp. 556-562(7)

Publisher: Oxford University Press

Molecular Determinants of Fluoroquinolone Antibacterial Agents Pharmacokinetics

Authors: Leveque, Dominique; Jehl, Francois

Source: Current Clinical Pharmacology, Volume 4, Number 3, September 2009 , pp. 191-197(7)

Publisher: Bentham Science Publishers

Evidence for moxifloxacin in community-acquired pneumonia: the impact of pharmaco-economic considerations on guidelines

Author: Simoens, Steven

Source: Current Medical Research and Opinion, Volume 25, Number 10, October 2009 , pp. 2447-2457(11)

Publisher: Informa Healthcare

Moxifloxacin: QT interval prolongation and torsade de pointes in an elderly patient: case report

Source: Reactions, Volume 1, Number 1273, 2009-10-10 , pp. 23-23(1)

Publisher: Adis International

Metronidazole/moxifloxacin: Orthostatic hypotension, nausea, vomiting and recurrent C. difficile infection, treated with nitazoxanide and probiotics: case report

Source: Reactions, Volume 1, Number 1273, 2009-10-10 , pp. 23-23(1)

Publisher: Adis International

Rate of bacterial eradication by ophthalmic solutions of fourth-generation fluoroquinolones

Authors: Callegan, Michelle; Novosad, Billy; Ramadan, Raniyah; Wiskur, Brandt; Moyer, Andrea

Source: Advances in Therapy, Volume 26, Number 4, April 2009 , pp. 447-454(8)

Publisher: Springer

Moxifloxacin-Containing Triple Therapy as Second-Line Treatment for Helicobacter pylori Infection: Effect of Treatment Duration and Antibiotic Resistance on the Eradication Rate

Authors: Yoon, Hyuk; Kim, Nayoung; Lee, Byoung Hwan; Hwang, Tae Jun; Lee, Dong Ho; Park, Young Soo; Nam, Ryoung Hee; Jung, Hyun Chae; Song, In Sung

Source: Helicobacter, Volume 14, Number 5, October 2009 , pp. 429-437(9)

Publisher: Blackwell Publishing

10 years' experience with the pneumococcal quinolone moxifloxacin

Authors: Burkhardt, Olaf; Welte, Tobias

Source: Expert Review of Anti-Infective Therapy, Volume 7, Number 6, August 2009 , pp. 645-668(24)

Publisher: Expert Reviews